口腔颌面-头颈黏膜黑色素瘤的诊治现状和进展

doi:10.3969/j.issn.1005-4979.2015.02.001

《口腔颌面外科杂志》 ›› 2015, Vol. 25 ›› Issue (2): 85-. doi: 10.3969/j.issn.1005-4979.2015.02.001

• 专家论坛 • 下一篇

口腔颌面-头颈黏膜黑色素瘤的诊治现状和进展

郭伟，宋浩

上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科，上海 200011

出版日期:2015-04-22 发布日期:2015-06-10
通讯作者: 郭伟，教授. E-mail:guoweicn@yahoo.com
作者简介:郭伟（1958—），男，山东人，博士，教授.
基金资助:
上海市科委资助项目（10410711200, 08140902100, 11495802000， 14DZ1941400）

The Present Therapeutic Strategies and Future Prospects of Oral and Maxillofacial-Head and Neck Mucosal Melanoma

GUO Wei, SONG Hao

Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai 9th People's Hospital, Shanghai Jiaotong University, Shanghai 200011, China

Online:2015-04-22 Published:2015-06-10

摘要/Abstract

摘要： 口腔颌面-头颈部是黏膜黑色素瘤的高发部位，该病侵袭性强，易发生区域和远处转移，预后很差，临床治疗有很大的难度。经过多年的临床经验总结，口腔黏膜黑色素瘤的综合序列治疗方法已经形成，治疗效果有所提高。近年来，随着分子生物学的迅速发展，肿瘤的分子诊断和靶向治疗取得了巨大突破，尤其是小分子抑制剂和免疫调节治疗的发展，打开了晚期黑色素瘤治疗的突破口。目前，口腔颌面-头颈黏膜黑色素瘤的治疗已向个体化治疗的方向发展。

关键词: 口腔颌面-头颈部； , 黏膜； , 黑色素瘤； , 靶向治疗； , 免疫调节； , 个体化治疗

Abstract: Oral and maxillofacial-head and neck are region with high incidence of mucosal melanoma. The neoplasm is rare but aggressive, with high incidence of regional or distant metastasis. The prognosis is extremely poor. Combined serial therapy had been established which had improved the outcome of patients. In recent years, with the rapid development of molecular biology, molecular diagnosis in oncology and targeted therapy, especially on pharmacological inhibitor and immunomodulation, had achieved major progress in the treatment of advanced melanoma. At present, personalized medicine is being introduced into the treatment of oral and maxillofacial-head and neck mucosal melanoma.

Key words: oral and maxillofacial-head and neck region, mucosa, melanoma, targeted therapy, immunomodulation, personalized medicine

中图分类号:

郭伟，宋浩. 口腔颌面-头颈黏膜黑色素瘤的诊治现状和进展[J]. 《口腔颌面外科杂志》, 2015, 25(2): 85-.

GUO Wei, SONG Hao. The Present Therapeutic Strategies and Future Prospects of Oral and Maxillofacial-Head and Neck Mucosal Melanoma[J]. 《Journal of Oral and Maxillofacial Surgery》, 2015, 25(2): 85-.

https://journal06.magtech.org.cn/Jweb_joms/CN/Y2015/V25/I2/85

参考文献

[1] Venables, PJ. Management of patients presenting with Sjogren's syndrome[J]. Best Pract Res Clin Rheumatol, 2006, 20(4):791-807.

[2] Fox RI. Sjogren's syndrome[J]. Lancet, 2005, 366(9482):321-331.

[3] Rasmussen A, Ice JA, Li H, et al. Comparison of the American-European Consensus Group Sjogren's syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort[J]. Ann Rheum Dis, 2014, 73(1):31-38.

[4] Shiboski SC, Shiboski CH, Criswell H, et al. American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort[J]. Arthritis Care Res (Hoboken), 2012, 64(4):475-487.

[5] Moutsopoulos HM. Sjogren's syndrome: a forty-year scientific journey[J]. J Autoimmun, 2014, 51:1-9.

[6] Takei M, Shiraiwa H, Azuma T, et al. The possible etiopathogenic genes of Sjogren's syndrome[J]. Autoimmun Rev, 2005, 4(7):479-484.

[7] Gottenberg, JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome[J]. Proc Natl Acad Sci U S A, 2006, 103(8):2770-2775.

[8] Ice JA. Li H, Adrianto I, et al. Genetics of Sjogren's syndrome in the genome-wide association era[J]. J Autoimmun, 2012, 39(1-2):57-63.

[9] Triantafyllopoulou A, Moutsopoulos H. Persistent viral infection in primary Sjogren's syndrome: review and perspectives[J]. Clin Rev Allergy Immunol, 2007, 32(3):210-214.

[10] Li J, Wang X, Zhang F, et al. Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases[J]. Pharmacol Ther, 2013, 138(3):441-451.

[11] Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjogren's syndrome[J]. J Autoimmun, 2010, 35(3):225-231.

[12] Akira S, Takeda K. Toll-like receptor signalling[J]. Nat Rev Immunol, 2004, 4(7): 499-511.

[13] Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA[J]. Nature, 2000, 408(6813):740-745.

[14] Savarese E, Chae OW, Trowitzsch S, et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7[J]. Blood, 2006, 107(8):3229-3234.

[15] Means TK, Latz E, Hayashi F, et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9 [J]. J Clin Invest, 2005, 115(2):407-417.

[16] Guerrier T, Le Pottier L, Devauchelle V, et al. Role of Toll-like receptors in primary Sjogren's syndrome with a special emphasis on B-cell maturation within exocrine tissues[J]. J Autoimmun, 2012, 39(1-2):69-76.

[17] Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword[J]. Nat Rev Immunol, 2003, 3(9):745-756.

[18] Dodeller F, Schulze-Koops H. The p38 mitogen-activated protein kinase signaling cascade in CD4 T cells[J]. Arthritis Res Ther, 2006, 8(2):205.

[19] Dominguez C, Powers DA, Tamayo N. p38 MAP kinase inhibitors: many are made, but few are chosen[J]. Curr Opin Drug Discov Devel, 2005, 8(4):421-430.

[20] Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies[J]. Arthritis Rheum, 2009, 60(5):1232-1241.

[21] Zheng L, Zhang Z, Yu C, et al. Expression of Toll-like receptors 7, 8, and 9 in primary Sjogren's syndrome[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2010, 109(6):844-850.

[22] Zheng L, Zhang Z, Yu C, et al. Association between IFN-alpha and primary Sjogren's syndrome[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2009, 107(1):e12-e18.

[23] Willeke PH, Schotte H, Schluter B, et al. Interleukin 1beta and tumour necrosis factor alpha secreting cells are increased in the peripheral blood of patients with primary Sjogren's syndrome[J]. Ann Rheum Dis, 2003, 62(4):359-362.

[24] Greenspan JS, Daniels TE, Talal N, et al. The histopathology of Sjogren's syndrome in labial salivary gland biopsies[J]. Oral Surg Oral Med Oral Pathol, 1974,37(2):217-229.

[25] Nakamura H, Kawakami A, Yamasaki S, et al. Expression of mitogen activated protein kinases in labial salivary glands of patients with Sjogren's syndrome[J]. Ann Rheum Dis, 1999, 58(6):382-385.

[26] Ping L, Ogawa N, Zhang Y, et al. p38 mitogen-activated protein kinase and nuclear factor-kappaB facilitate CD40-mediated salivary epithelial cell death[J]. J Rheumatol, 2012, 39(6):1256-1264.

[27] Cha S, Peck AB, Humphreys-Beher MG. Progress in understanding autoimmune exocrinopathy using the non-obese diabetic mouse: an update[J]. Crit Rev Oral Biol Med, 2002, 13(1):5-16.

[28] Chiorini JA, Cihakova D, Ouellette CE, et al. Sjogren syndrome: advances in the pathogenesis from animal models[J]. J Autoimmun, 2009, 33(3-4):190-196.

[29] Cha S, Nagashima H, Brown VB, et al. Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjogren's syndrome) on a healthy murine background[J]. Arthritis Rheum, 2002, 46(5):1390-1398.

[30] Robinson CP, Yamachika S, Bounous DI, et al. A novel NOD-derived murine model of primary Sjogren's syndrome[J]. Arthritis Rheum, 1998, 41(1):150-156.

[31] Lindqvist AK, Nakken B, Sundler M, et al. Influence on spontaneous tissue inflammation by the major histocompatibility complex region in the nonobese diabetic mouse[J]. Scand J Immunol, 2005, 61(2):119-127.

[32] Ridgway WM, Peterson LB, Todd JA, et al. Gene-gene interactions in the NOD mouse model of type 1 diabetes[J]. Adv Immunol, 2008, 100:151-175.

[33] Yamano S, Atkinson JC, Baum BJ, et al. Salivary gland cytokine expression in NOD and normal BALB/c mice[J]. Clin Immunol, 1999, 92(3):265-275.

选择文件类型/文献管理软件名称

选择包含的内容

口腔颌面-头颈黏膜黑色素瘤的诊治现状和进展

The Present Therapeutic Strategies and Future Prospects of Oral and Maxillofacial-Head and Neck Mucosal Melanoma

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

本文评价

[1]	马旭辉，王丽珍，任国欣，吴云腾，顾挺，郭伟. SOX10作为原发性口腔黏膜恶性黑色素瘤分子诊断指标的初步研究[J]. 《口腔颌面外科杂志》, 2019, 29(3): 131-.
[2]	王中和. 口腔颌面-头颈恶性肿瘤治疗的新策略：放疗联合个体化靶向治疗[J]. 《口腔颌面外科杂志》, 2014, 24(5): 325-.
[3]	章臻1，潘巨利1，黄欣2，陈溯1，陈仁吉3，温颖4. 下颌骨缺损的个体化修复重建[J]. 《口腔颌面外科杂志》, 2014, 24(4): 293-.
[4]	王中和. 口腔颌面-头颈部恶性肿瘤的同步放化疗[J]. 《口腔颌面外科杂志》, 2013, 23(6): 403-408.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

口腔颌面-头颈黏膜黑色素瘤的诊治现状和进展

The Present Therapeutic Strategies and Future Prospects of Oral and Maxillofacial-Head and Neck Mucosal Melanoma

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

本文评价